Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys

[1]  B. Murphy,et al.  Severe Acute Respiratory Syndrome Coronavirus Infection of Golden Syrian Hamsters , 2005, Journal of Virology.

[2]  Pegylated Interferon-alpha Protects Type 1 Pneumocytes Against SARS Coronavirus Infection in Macaques , 2004 .

[3]  B. Murphy,et al.  Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS , 2004, The Lancet.

[4]  Michelle M. Packard,et al.  Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of Mice , 2004, Journal of Virology.

[5]  Ton de Jong,et al.  Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques , 2004, Nature Medicine.

[6]  M. Drebot,et al.  Susceptibility of Pigs and Chickens to SARS Coronavirus , 2004, Emerging infectious diseases.

[7]  W. Bellini,et al.  Effects of a SARS-associated coronavirus vaccine in monkeys , 2003, The Lancet.

[8]  Albert D. M. E. Osterhaus,et al.  SARS virus infection of cats and ferrets , 2003, Nature.

[9]  J. Peiris,et al.  Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome , 2003, The Lancet.

[10]  L. Poon,et al.  Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study , 2003 .

[11]  J. A. Comer,et al.  A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[12]  Malik Peiris,et al.  Aetiology: Koch's postulates fulfilled for SARS virus , 2003, Nature.

[13]  Christian Drosten,et al.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[14]  Arthur S Slutsky,et al.  Identification of severe acute respiratory syndrome in Canada. , 2003, The New England journal of medicine.

[15]  The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys. , 2002, Vaccine.

[16]  T. Kuiken,et al.  Pathogenesis of Influenza A (H5N1) Virus Infection in a Primate Model , 2001, Journal of Virology.

[17]  B. Murphy,et al.  African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types-1, -2, and -3 infection. , 2000, Vaccine.

[18]  R. Chanock,et al.  A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. , 1993, Vaccine.

[19]  R. Webster,et al.  Virulence of Avian Influenza A Viruses for Squirrel Monkeys , 1982, Infection and immunity.

[20]  F. Scott,et al.  Pathogenesis of feline infetious peritonitis: pathologic changes and immunofluorescence. , 1981, American journal of veterinary research.

[21]  Scott Fw,et al.  Pathogenesis of feline infectious peritonitis: nature and development of viremia. , 1981 .

[22]  F. Scott,et al.  Pathogenesis of feline infectious peritonitis: nature and development of viremia. , 1981, American journal of veterinary research.

[23]  Petersen Nc,et al.  Immunologic phenomena in the effusive form of feline infectious peritonitis. , 1980 .

[24]  J. Boyle,et al.  Immunologic phenomena in the effusive form of feline infectious peritonitis. , 1980, American journal of veterinary research.